Search

Your search keyword '"Mazzuoli, S."' showing total 165 results
Start Over Author "Mazzuoli, S."
165 results on '"Mazzuoli, S."'

1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

3. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

4. A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding

Author

Pallotta, L., Vitale, M.A., Parodi, M.C., Balzano, A., Sturniolo, G.C., Lamboglia, F., D’Angelo, A., Testai, F.V., Frosini, G., Marini, M., D’Amico, G., Montalbano, L.M., Sinagra, E., Macarri, G., Antonini, F., Occhigrossi, G., Caliendo, S., Campaioli, M., Peccianti, C., Spotti, D., Colucci, A., Marin, R., Cervellin, E., Conio, M., De Matthaeis, M., Biagini, M., Scarpulla, G., Camilleri, S., Lauri, A., De Fanis, C., Craxì, A., Peralta, S., Kohn, A., Tesi, A., Azzurro, M., Ferronato, A., Conigliaro, R., Manno, M., Manta, R., Adamo, S., Brunelli, E., Ridolfi, F., De Boni, M., De Bona, M., Guglielmi, F.W., Mazzuoli, S., Occhipinti, P., Ventrucci, M., Pozzato, P., Milani, S., Virgilio, C., Costa, G., Di Bella, S., Tammaro, Leonardo, Buda, Andrea, Di Paolo, Maria Carla, Zullo, Angelo, Hassan, Cesare, Riccio, Elisabetta, Vassallo, Roberto, Caserta, Luigi, Anderloni, Andrea, and Natali, Alessandro

Published
2014
Full Text
View/download PDF

5. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

7. IBD and Covid-19 in Italy: comparisons between first and second pandemic wave

Author

Bezzio, C., Costa, S., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Bossa, F., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Alessandro Armuzzi, Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Fiorino, G., Vernero, M., and Saibeni, S.

Subjects
covid-19, inflammatory bowel disease, outcomes
Published
2022

8. P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave

Author

Bezzio, C, primary, Costa, S, additional, Armuzzi, A, additional, Furfaro, F, additional, Ardizzone, S, additional, Milla, M, additional, Bossa, F, additional, Orlando, A, additional, Caprioli, F A, additional, Castiglione, F, additional, Viganò, C, additional, Ribaldone, D G, additional, Zingone, F, additional, Monterubbianesi, R, additional, Imperatore, N, additional, Festa, S, additional, Daperno, M, additional, Scucchi, L, additional, Ferronato, A, additional, Pastorelli, L, additional, Balestrieri, P, additional, Ricci, C, additional, Cappello, M, additional, Felice, C, additional, Coppini, F, additional, Alvisi, P, additional, Gerardi, V, additional, Variola, A, additional, Mazzuoli, S, additional, Lenti, M V, additional, Alessandro, S, additional, Buda, A, additional, Micheli, F, additional, Ciardo, V, additional, Casella, G, additional, Viscido, A, additional, Bodini, G, additional, Fiorino, G, additional, Vernero, M, additional, and Saibeni, S, additional

Published
2022
Full Text
View/download PDF

9. P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors

Author

Onali, S, primary, Pugliese, D, additional, Caprioli, F A, additional, Orlando, A, additional, Biancone, L, additional, Nardone, O M, additional, Imperatore, N, additional, Fiorino, G, additional, Cappello, M, additional, Viola, A, additional, Principi, M B, additional, Bezzio, C, additional, Aratari, A, additional, Carparelli, S, additional, Mazzuoli, S, additional, Manguso, F, additional, Grossi, L, additional, Bodini, G, additional, Ribaldone, D, additional, Mocci, G, additional, Minerba, L, additional, Favale, A, additional, Grova, M, additional, Scucchi, L, additional, Segato, S, additional, Fries, W, additional, Castiglione, F, additional, Armuzzi, A, additional, and Fantini, M C, additional

Published
2022
Full Text
View/download PDF

10. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study

Author

Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Bezzio, Cristina, Armuzzi, Alessandro, Furfaro, Federica, Ardizzone, Sandro, Milla, Monica, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide Giuseppe, Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Fiorino, Gionata, Saibeni, Simone, and Francesca Coppini, Patrizia Alvisi, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Daniela Pugliese, Mariangela Allocca, Francesca Ferretti, Jenny Roselli, Fabrizio Bossa, Alessandra Giuliano, Nicole Piazza, Gianpiero Manes, Alessandro Sartini, Andrea Buda, Federica Micheli, Valeria Ciardo, Giovanni Casella, Angelo Viscido, Giorgia Bodini, Valentina Casini, Alessandra Soriano, Arnaldo Amato, Laurino Grossi, Sara Onali, Matteo Rottoli, Rocco Spagnuolo, Stefania Baroni, Claudio Cortelezzi, Monia Baldoni, Marta Vernero, Franco Scaldaferri, Giovanni Maconi, Alessia Dalila Guarino, Andrea Palermo, Renata D'Incà, Maria Lia Scribano, Livia Biancone, Lucio Carrozza, Marta Ascolani, Francesco Costa, Antonio Di Sabatino, Irene Zammarchi, Matteo Gottin, Francesco Simone Conforti

Subjects
medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, IBD, Population, Ulcerative, Disease, Lower risk, Asymptomatic, Inflammatory bowel disease, Aged, Humans, SARS-CoV-2, Tumor Necrosis Factor Inhibitors, COVID-19, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, IBD Treatments and Sars‐cov‐2 Infection, Internal medicine, medicine, biologics, Pharmacology (medical), education, therapy, education.field_of_study, Hepatology, business.industry, INFLAMMATORY BOWEL DISEASE, Gastroenterology, medicine.disease, Colitis, Ulcerative colitis, Pneumonia, Original Article, medicine.symptom, business, Cohort study
Abstract

Summary Background Older age and comorbidities are the main risk factors for adverse COVID‐19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID‐19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS‐CoV‐2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID‐19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune‐mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID‐19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID‐19 outcomes, but anti‐TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID‐19 in CD. Conclusion The course of COVID‐19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID‐19 re‐vaccination or for therapies for SARS‐CoV‐2 infection., The course of COVID‐19 in patients with IBD patients is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks.

Published
2021

11. Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Author

Pugliese, D, Privitera, G, Rogai, F, Variola, A, Viola, A, Laterza, L, Privitera, Ac, Allocca, M, Bossa, F, Cappello, M, Daperno, M, Lorenzon, G, Mazzuoli, S, Principi, M, Sablich, R, Moser, L, Ferronato, A, Traini, S, Tapete, G, Bodini, G, Di Girolamo, M, Grossi, L, Mocci, G, Ricci, C, Saibeni, S, Festa, S, Spagnuolo, R, Cortelezzi, Cc, Mocciaro, F, Rizzello, F, Armuzzi, A, and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD

Subjects
remission, naïve, persistence, Golimumab, ulcerative colitis
Published
2021

13. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism: Multicentre prospective study by the ‘Nutritional Problems in Gastroenterology’ Section of the Italian Society of Gastroenterology (SIGE)

Author

Guglielmi, F.W., Panella, C., Buda, A., Budillon, G., Caregaro, L., Clerici, C., Conte, D., Federico, A., Gasbarrini, G., Guglielmi, A., Loguercio, C., Losco, A., Martines, D., Mazzuoli, S., Merli, M., Mingrone, G., Morelli, A., Nardone, G., Zoli, G., and Francavilla, A.

Published
2005
Full Text
View/download PDF

20. The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy

Author

Armuzzi, A. (ORCID:0000-0003-1572-0118), Fiorino, G., Variola, A., Manetti, N., Fries, W., Orlando, A., Maconi, G., Bossa, F., Cappello, M., Biancone, L., Cantoro, L., Costa, F., D'Inca, R., Lionetti, P., Principi, M., Castiglione, F., Annunziata, M. L., Di Sabatino, A., Di Girolamo, M., Terpin, M. M., Cortelezzi, C. C., Saibeni, S., Amato, A., Ardizzone, S., Guidi, L. (ORCID:0000-0003-3320-7094), Danese, S., Massella, A., Ventra, A., Rizzuto, G., Massari, A., Perri, F., Annese, V., Saettone, S., Tari, R., Petruzzellis, C., Meucci, G., Imperiali, G., Guglielmi, F. W., Mazzuoli, S., Caserta, L., Parodi, M. C., Colli, A., Ronchetti, A., Pugliese, D., Geccherle, A., Rogai, F., Milani, S., Renna, S., Cassinotti, A., Andriulli, A., Martino, G., Scrivo, B., Troncone, E., Kohn, A., Bertani, L., Lorenzon, G., Ghione, S., Nardone, O., Vecchi, M., Bertani, A., Bosani, M. A., Bezzio, C., Salerno, R., Armuzzi, A. (ORCID:0000-0003-1572-0118), Fiorino, G., Variola, A., Manetti, N., Fries, W., Orlando, A., Maconi, G., Bossa, F., Cappello, M., Biancone, L., Cantoro, L., Costa, F., D'Inca, R., Lionetti, P., Principi, M., Castiglione, F., Annunziata, M. L., Di Sabatino, A., Di Girolamo, M., Terpin, M. M., Cortelezzi, C. C., Saibeni, S., Amato, A., Ardizzone, S., Guidi, L. (ORCID:0000-0003-3320-7094), Danese, S., Massella, A., Ventra, A., Rizzuto, G., Massari, A., Perri, F., Annese, V., Saettone, S., Tari, R., Petruzzellis, C., Meucci, G., Imperiali, G., Guglielmi, F. W., Mazzuoli, S., Caserta, L., Parodi, M. C., Colli, A., Ronchetti, A., Pugliese, D., Geccherle, A., Rogai, F., Milani, S., Renna, S., Cassinotti, A., Andriulli, A., Martino, G., Scrivo, B., Troncone, E., Kohn, A., Bertani, L., Lorenzon, G., Ghione, S., Nardone, O., Vecchi, M., Bertani, A., Bosani, M. A., Bezzio, C., and Salerno, R.

Abstract

Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.

Published
2019

23. OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY

Author

Festa, S., primary, Scribano, M.L., additional, Pugliese, D., additional, Sarli, E., additional, Bezzio, C., additional, Principi, M.B., additional, Ribaldone, D.G., additional, Allocca, M., additional, Mocci, G., additional, Bodini, G., additional, Spagnuolo, R., additional, Vernia, P., additional, Mazzuoli, S., additional, Laino, G., additional, Barberio, B., additional, Zerboni, G., additional, Aratari, A., additional, and Papi, C., additional

Published
2019
Full Text
View/download PDF

24. P.07.14 INTER-OBSERVER AGREEMENT OF ULCERATIVE COLITIS “EXTENDED MAYO ENDOSCOPIC SCORE (EMES)” WITHIN A MULTICENTER INFLAMMATORY BOWEL DISEASE (IBD) TEAM WORK

Author

Contaldo, A., primary, Bianchi, F.P., additional, Losurdo, G., additional, Iannone, A., additional, Albano, F., additional, Allegretta, L., additional, Bossa, F., additional, De Tullio, N., additional, Valle, N. Della, additional, Fiorella, S., additional, Hadad, Y., additional, Mazzuoli, S., additional, Paiano, P., additional, Rispo, A., additional, Stasi, E., additional, Tursi, A., additional, Ierardi, E., additional, Tafuri, S., additional, Principi, M., additional, and Di Leo, A., additional

Published
2019
Full Text
View/download PDF

25. OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY

Author

Pugliese, D., primary, Daperno, M., additional, Fiorino, G., additional, Savarino, E., additional, Mosso, E., additional, Biancone, L., additional, Testa, A., additional, Sarpi, L., additional, Cappello, M., additional, Bodini, G., additional, Caprioli, F., additional, Festa, S., additional, Laino, G., additional, Maconi, G., additional, Mazzuoli, S., additional, Mocci, G., additional, Sartini, A., additional, D'Amore, A., additional, Alivernini, S., additional, Gremese, E., additional, and Armuzzi, A., additional

Published
2019
Full Text
View/download PDF

26. P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study

Author

Pugliese, D, primary, Daperno, M, additional, Fiorino, G, additional, Savarino, E, additional, Mosso, E, additional, Biancone, L, additional, Testa, A, additional, Sarpi, L, additional, Cappello, M, additional, Bodini, G, additional, Caprioli, F, additional, Festa, S, additional, Laino, G, additional, Maconi, G, additional, Mazzuoli, S, additional, Mocci, G, additional, Sartini, A, additional, D'Amore, A, additional, Alivernini, S, additional, Gremese, E, additional, and Armuzzi, A, additional

Published
2019
Full Text
View/download PDF

27. P783 Long-term colectomy rate in acute severe ulcerative colitis. An observational multi-centre study on behalf of IG-IBD (Italian group for the study of inflammatory bowel disease)

Author

Festa, S, primary, Scribano, M L, additional, Pugliese, D, additional, Sarli, E, additional, Bezzio, C, additional, Principi, M B, additional, Ribaldone, D G, additional, Allocca, M, additional, Mocci, G, additional, Bodini, G, additional, Spagnuolo, R, additional, Vernia, P, additional, Mazzuoli, S, additional, Laino, G, additional, Barberio, B, additional, Zerboni, G, additional, Aratari, A, additional, and Papi, C, additional

Published
2019
Full Text
View/download PDF

28. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD

Author

Fiorino, G., Manetti, N., Variola, A., Bossa, F., Rizzuto, G., Guidi, L., Maconi, G., Ghione, S., Cantoro, L., Lorenzon, G., Fries, W., Annunziata, M. L., Costa, F., Terpin, M. M., Principi, B., Cortelezzi, C., Biancone, L., Amato, A., Occhipinti, P., Mazzuoli, S., Ardizzone, S., Di Girolamo, M., Alvisi, P., Meucci, G., Caserta, L., Saibeni, S., Petruzzellis, C., Ronchetti, A., Cappello, M., Castiglione, F., Danese, S., Massella, A., Varvara, D., Orlando, A., Armuzzi, A., Massari, A., Lionetti, P., Kohn, A., Renata D'Incà, Vecchi, M., Bertani, L., Annese, V., Fiorino, G, Manetti, N, Variola, A, Bossa, F, Rizzuto, G, Guidi, L, Maconi, G, Ghione, S, Cantoro, L, Lorenzon, G, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Principi, B, Cortelezzi, C, Biancone, L, Amato, A, Occhipinti, P, Mazzuoli, S, Ardizzone, S, Di Girolamo, M, Alvisi, P, Meucci, G, Caserta, L, Saibeni, S, Petruzzellis, C, Ronchetti, A, Cappello, M, Castiglione, F, Danese, S, Massella, A, Varvara, D, Orlando, A, Armuzzi, A, Massari, A, Lionetti, P, Kohn, A, D'Inca, R, Vecchi, M, Bertani, L, and Annese, V

Published
2016

29. The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars

Author

Fiorino G, Manetti N, Variola A, Bossa F, Rizzuto G, Armuzzi A, Massari A, Ghione S, Cantoro L, Lorenzon G, Fries W, Annunziata ML, Costa F, Terpin MM, Principi M, Cortelezzi CC, Biancone L, Amato A, Occhipinti P, Mazzuoli S, Ardizzone S, Di Girolamo M, Alvisi P, Meucci G, Caserta L, Saibeni S, Petruzzzellis C, Ronchetti A, Cappello M, Castiglione F, Danese S, Massella A, Varvara D, Orlando A, Annese V, Fiorino, G, Manetti, N, Variola, A, Bossa, F, Rizzuto, G, Armuzzi, A, Massari, A, Ghione, S, Cantoro, L, Lorenzon, G, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Principi, M, Cortelezzi, Cc, Biancone, L, Amato, A, Occhipinti, P, Mazzuoli, S, Ardizzone, S, Di Girolamo, M, Alvisi, P, Meucci, G, Caserta, L, Saibeni, S, Petruzzzellis, C, Ronchetti, A, Cappello, M, Castiglione, F, Danese, S, Massella, A, Varvara, D, Orlando, A, and Annese, V

Published
2016

30. P.07.12 CLINICAL RESPONSE, EFFECTIVENESS, SAFETY AND MUCOSAL HEALING INDUCTION OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A PRELIMINARY REAL-LIFE MULTICENTRIC EXPERIENCE IN SOUTHERN ITALY

Author

Contaldo, A., primary, Losurdo, G., additional, Bossa, F., additional, Biscaglia, G., additional, Mazzuoli, S., additional, Fanigliulo, L., additional, Tursi, A., additional, Lovero, R., additional, Ierardi, E., additional, Principi, M.B., additional, and Di Leo, A., additional

Published
2018
Full Text
View/download PDF

31. P.02.10 REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD)

Author

Pugliese, D., primary, Rogai, F., additional, Variola, A., additional, Viola, A., additional, Privitera, A.C., additional, Allocca, M., additional, Bossa, F., additional, Cappello, M., additional, Lorenzon, G., additional, Mazzuoli, S., additional, Principi, M.B., additional, Sablich, R., additional, Ferronato, A., additional, Festa, S., additional, Moser, L., additional, Tapete, G., additional, Bodini, G., additional, Di Girolamo, M., additional, Grossi, L., additional, Mocci, G., additional, Mocciaro, F., additional, Ricci, C., additional, Saibeni, S., additional, Spagnuolo, R., additional, Cortelezzi, C.C., additional, Orlandini, B., additional, Capoferro, E., additional, Costantino, G., additional, and Armuzzi, A., additional

Published
2018
Full Text
View/download PDF

32. Prevalence of home artificial nutrition in Italy in 2005: a survey by the Italian Society for Parenteral and Enteral Nutrition (SINPE)

Author

PIRONI L, CANDUSSO M, BIONDO A, BOSCO A, CASTALDI P, CONTALDO F, FINOCCHIARO E, GIANNONI A, MAZZUOLI S, ORLANDONI P, PALOZZO A, PANELLA C, PASTÒ S, RUGGERI E, SANDRI G, STELLA E, ITALIAN SOCIETY FOR PARENTERAL AND ENTERAL NUTRITION EXECUTIVE COMMITTEE, TOIGO, GABRIELE, Pironi, L, Candusso, M, Biondo, A, Bosco, A, Castaldi, P, Contaldo, F, Finocchiaro, E, Giannoni, A, Mazzuoli, S, Orlandoni, P, Palozzo, A, Panella, C, Pastò, S, Ruggeri, E, Sandri, G, Stella, E, Toigo, Gabriele, ITALIAN SOCIETY FOR PARENTERAL AND ENTERAL NUTRITION EXECUTIVE, Committee, Pironi, Lori, Candusso, M., Biondo, A., Bosco, A., Castaldi, P., Contaldo, F., Finocchiaro, E., Giannoni, A., Mazzuoli, S., Orlandoni, P., Palozzo, A., Panella, C., Pasto, S., Ruggeri, E., Sandri, G., Stella, E., and Toigo, G.

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Artificial nutrition, Disease, Critical Care and Intensive Care Medicine, Primary disease, Enteral administration, Enteral Nutrition, Patient age, Neoplasms, Surveys and Questionnaires, Epidemiology, Prevalence, medicine, Humans, Home artificial nutrition, epidemiology, Child, Nutrition and Dietetics, business.industry, Public health, HOME ENTERAL NUTRITION, nutritional and metabolic diseases, Intestinal Diseases, stomatognathic diseases, Parenteral nutrition, Italy, HOME PARENTERAL NUTRITION, Health Care Surveys, Female, Nervous System Diseases, Parenteral Nutrition, Home, business, Demography
Abstract

Summary Aim To determine the prevalence (cases per million inhabitants) of home artificial nutrition (HAN), enteral (HEN) and parenteral (HPN), in Italy, grouped according to administrative regions, patient age and primary disease, and to analyze the impact both of the presence of an HAN regional regulation and of demographic characteristics. Methods In April 2005, the Regional Coordinators of the Italian Society for Parenteral and Enteral Nutrition (SINPE) recorded all the ongoing cases of HAN using a structured questionnaire and were asked to estimate the representativeness of the collected sample with respect to the total expected HAN. Results A total of 6955 cases of HAN (93.5% adults, 6.5% pediatric patients ⩽18 years) were recorded in 16 of the 20 Italian regions (80% of the Italian population; sample representativeness 78%). HAN prevalence 152.6 (83.9% HEN, 16.1% HPN); the HAN range among the regions was: prevalence 28.1–519.8; oncological disease 13.8–75.7%, neurological disease 15.5–79.9%, intestinal failure 1.3–14.0%. An HAN regulation was present in 11 regions. A positive association ( P = 0.012 ) was found between the number of years since the regulation was issued and the HAN prevalence, and also between the % neurological patients and the population density ( P = 0.130 ) and the % inhabitants ⩾75 years ( P = 0.040 ). Conclusions The need for HAN regards a great number of patients throughout the country; there are substantial differences between the regions with respect to both the prevalence and the use of HAN in various disease categories. A specific regulation may favor the development of HAN.

Published
2007

35. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism Multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology

Author

GUGLIELMI FW, PANELLA C, BUDA A, CAREGARO L, CLERICI C, CONTE D, FEDERICO A, GASBARRINI G, GUGLIELMI A, LOGUERCIO C, LOSCO A, MARTINES D, MAZZUOLI S, MERLI M, MINGRONE G, MORELLI A, ZOLI G, FRANCAVILLA A., BUDILLON, GABRIELE, NARDONE, GERARDO ANTONIO PIO, Guglielmi, Fw, Panella, C, Buda, A, Budillon, Gabriele, Caregaro, L, Clerici, C, Conte, D, Federico, A, Gasbarrini, G, Guglielmi, A, Loguercio, C, Losco, A, Martines, D, Mazzuoli, S, Merli, M, Mingrone, G, Morelli, A, Nardone, GERARDO ANTONIO PIO, Zoli, G, and Francavilla, A.

Subjects
Hypermetabolism, Liver Cirrhosi, Nutritional state
Abstract

BACKGROUND AND AIMS: A total of 334 stable, compensated cirrhotic patients admitted to 10 Italian Gastroenterology Units were included in a prospective study to evaluate nutritional state and energy balance in liver cirrhosis. MATERIALS AND METHODS: Nutritional state and calorie intake were examined in the total population, while adequacy of calorie intake versus measured total energy expenditure was evaluated in a comparable subpopulation and in 40 matched controls, by computing the energy balance. RESULTS: Our data demonstrated that: (i) malnutrition was present in 25% of the total patients and significantly correlated with the Child's group (A=16%; B=25%; C=44%); (ii) the type of malnutrition is influenced by mBEE: normometabolic patients exhibit a significant (p

Published
2005

41. A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding

Author

Tammaro, Leonardo, primary, Buda, Andrea, additional, Di Paolo, Maria Carla, additional, Zullo, Angelo, additional, Hassan, Cesare, additional, Riccio, Elisabetta, additional, Vassallo, Roberto, additional, Caserta, Luigi, additional, Anderloni, Andrea, additional, Natali, Alessandro, additional, Pallotta, L., additional, Vitale, M.A., additional, Parodi, M.C., additional, Balzano, A., additional, Sturniolo, G.C., additional, Lamboglia, F., additional, D’Angelo, A., additional, Testai, F.V., additional, Frosini, G., additional, Marini, M., additional, D’Amico, G., additional, Montalbano, L.M., additional, Sinagra, E., additional, Macarri, G., additional, Antonini, F., additional, Occhigrossi, G., additional, Caliendo, S., additional, Campaioli, M., additional, Peccianti, C., additional, Spotti, D., additional, Colucci, A., additional, Marin, R., additional, Cervellin, E., additional, Conio, M., additional, De Matthaeis, M., additional, Biagini, M., additional, Scarpulla, G., additional, Camilleri, S., additional, Lauri, A., additional, De Fanis, C., additional, Craxì, A., additional, Peralta, S., additional, Kohn, A., additional, Tesi, A., additional, Azzurro, M., additional, Ferronato, A., additional, Conigliaro, R., additional, Manno, M., additional, Manta, R., additional, Adamo, S., additional, Brunelli, E., additional, Ridolfi, F., additional, De Boni, M., additional, De Bona, M., additional, Guglielmi, F.W., additional, Mazzuoli, S., additional, Occhipinti, P., additional, Ventrucci, M., additional, Pozzato, P., additional, Milani, S., additional, Virgilio, C., additional, Costa, G., additional, and Di Bella, S., additional

Published
2014
Full Text
View/download PDF

46. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE)

Author

Guglielmi, Fw, Panella, C, Buda, A, Budillon, G, Caregaro, L, Clerici, Carlo, Conte, D, Federico, A, Gasbarrini, Giovanni Battista, Guglielmi, A, Loguercio, C, Losco, A, Martines, D, Mazzuoli, S, Merli, M, Mingrone, Geltrude, Morelli, Alessia, Nardone, Gerardo, Zoli, G, Francavilla, A, Mingrone, Geltrude (ORCID:0000-0003-2021-528X), Guglielmi, Fw, Panella, C, Buda, A, Budillon, G, Caregaro, L, Clerici, Carlo, Conte, D, Federico, A, Gasbarrini, Giovanni Battista, Guglielmi, A, Loguercio, C, Losco, A, Martines, D, Mazzuoli, S, Merli, M, Mingrone, Geltrude, Morelli, Alessia, Nardone, Gerardo, Zoli, G, Francavilla, A, and Mingrone, Geltrude (ORCID:0000-0003-2021-528X)

Abstract

A total of 334 stable, compensated cirrhotic patients admitted to 10 Italian Gastroenterology Units were included in a prospective study to evaluate nutritional state and energy balance in liver cirrhosis.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results